[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Hall RL, Leahy MF: Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment. Eur J Haematol; 2001 Mar;66(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired Factor VIII autoantibody: four cases demonstrating the heterogenous nature of this condition and problems involved in diagnosis and treatment.
  • The development of an autoantibody to human Factor VIII is rare and presents many problems for diagnosis and treatment.
  • A wide range of treatment modalities were used in these cases with no gold standard of treatment or widely accepted guidelines existing.
  • We describe four cases which demonstrate the heterogeneity of this condition and its treatment and review the recent literature on the subject.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arthritis, Rheumatoid / complications. Azathioprine / therapeutic use. Breast Neoplasms. Cardiovascular Agents / therapeutic use. Cardiovascular Diseases / complications. Cardiovascular Diseases / drug therapy. Chlorambucil / therapeutic use. Cyclophosphamide / therapeutic use. Female. Hematoma / etiology. Humans. Immunoglobulin G / immunology. Immunosuppressive Agents / therapeutic use. Infection / etiology. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Male. Neoplasms, Multiple Primary. Partial Thromboplastin Time. Prednisolone / therapeutic use. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11350490.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Cardiovascular Agents; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; 9001-27-8 / Factor VIII; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine
  •  go-up   go-down


2. O'Rielly DD, Rahman P: Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med; 2010;3:15-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.
  • Rheumatoid arthritis (RA) is a chronic heterogeneous autoimmune disorder of unknown etiology resulting in inflammation in the synovium, cartilage, and bone.
  • Genetic factors are also important in RA pharmacotherapy due to the gene-dependent activity of enzymes involved in the pharmacokinetics and/or pharmacodynamics of RA medications.
  • Indeed, there is great variability in drug efficacy as well as adverse events associated with any anti-rheumatic therapy and genetics is thought to contribute significantly to this inter-individual variability in response.
  • We will also review the therapeutic agents that are currently being utilized or presently being evaluated in the treatment of RA, along with potential pharmacogenetic markers that have been proposed for such medications.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1978 Apr 20;298(16):869-71 [147420.001]
  • [Cites] Rheum Dis Clin North Am. 1992 Nov;18(4):741-59 [1280845.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):844-9 [1818543.001]
  • [Cites] Arthritis Rheum. 1987 Nov;30(11):1205-13 [2446635.001]
  • [Cites] Clin Genet. 1989 Sep;36(3):178-82 [2676268.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] Cell. 1986 Aug 29;46(5):705-16 [3091258.001]
  • [Cites] Am J Hum Genet. 1988 Oct;43(4):414-21 [3177384.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] J Rheumatol. 1995 Jun;22(6):1032-6 [7674226.001]
  • [Cites] J Clin Invest. 1993 Sep;92(3):1387-93 [7690781.001]
  • [Cites] Pharmacogenetics. 1994 Feb;4(1):39-42 [8004131.001]
  • [Cites] Am J Gastroenterol. 1993 Aug;88(8):1198-205 [8338087.001]
  • [Cites] Gut. 1995 Nov;37(5):674-8 [8549944.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1937-41 [8596047.001]
  • [Cites] J Inherit Metab Dis. 1996;19(5):589-94 [8892013.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Clin Exp Immunol. 1998 Sep;113(3):401-6 [9737669.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2856-62 [9763570.001]
  • [Cites] Crit Rev Immunol. 1998;18(5):389-418 [9784967.001]
  • [Cites] Ann Intern Med. 1998 Nov 1;129(9):716-8 [9841604.001]
  • [Cites] Arthritis Rheum. 1998 Dec;41(12):2196-204 [9870876.001]
  • [Cites] Arthritis Rheum. 1999 Jun;42(6):1071-9 [10366098.001]
  • [Cites] Scand J Gastroenterol Suppl. 1999;230:111-5 [10499471.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Arthritis Rheum. 2000 Jan;43(1):30-7 [10643697.001]
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001158 [10796420.001]
  • [Cites] J Immunol. 2001 Mar 15;166(6):4177-84 [11238669.001]
  • [Cites] Gut. 2001 May;48(5):591-2 [11302950.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):51-4 [11372592.001]
  • [Cites] Lancet. 2001 Sep 15;358(9285):903-11 [11567728.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Nov;15(11):1699-708 [11683683.001]
  • [Cites] Arthritis Rheum. 2001 Nov;44(11):2525-30 [11710708.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):237-44 [11882361.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):180-3 [11886967.001]
  • [Cites] Gut. 2002 Apr;50(4):485-9 [11889067.001]
  • [Cites] Hum Immunol. 2002 Jan;63(1):76-81 [11916172.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):183-90 [11927833.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):921-8 [11953968.001]
  • [Cites] Semin Arthritis Rheum. 2002 Jun;31(6):355-60 [12077707.001]
  • [Cites] Pharmacogenetics. 2002 Aug;12(6):429-36 [12172211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12281-6 [12213961.001]
  • [Cites] J Immunol. 2002 Oct 15;169(8):4388-98 [12370372.001]
  • [Cites] Ann Rheum Dis. 2003 Jan;62(1):4-9 [12480661.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):593-600 [12684695.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1398-407 [12746913.001]
  • [Cites] Ann Rheum Dis. 2003 Jun;62(6):526-9 [12759288.001]
  • [Cites] Nat Genet. 2003 Aug;34(4):395-402 [12833157.001]
  • [Cites] Rheumatology (Oxford). 2004 Feb;43(2):156-63 [12923290.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):221-4 [14505215.001]
  • [Cites] Drug Saf. 2003;26(13):983-9 [14583072.001]
  • [Cites] Genes Immun. 2004 May;5(3):151-7 [14749714.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):400-12 [14872482.001]
  • [Cites] Pharm Res. 2004 Feb;21(2):324-9 [15032315.001]
  • [Cites] Arthritis Res Ther. 2004;6(2):R142-50 [15059278.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2167-79 [15152062.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):330-7 [15208781.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):186-91 [15228163.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2113-21 [15248208.001]
  • [Cites] Nat Immunol. 2004 Oct;5(10):1052-60 [15334086.001]
  • [Cites] Ann Rheum Dis. 2005 Apr;64(4):575-81 [15345504.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1227-31 [15361376.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2750-6 [15457442.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2766-74 [15457444.001]
  • [Cites] Arthritis Rheum. 2004 Oct;50(10):3093-103 [15476205.001]
  • [Cites] Int J Clin Pharmacol Ther. 2004 Sep;42(9):496-503 [15487808.001]
  • [Cites] Immunol Rev. 2004 Dec;202:139-56 [15546391.001]
  • [Cites] Pharmacogenetics. 2004 Nov;14(11):733-9 [15564880.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):219-24 [15641066.001]
  • [Cites] Rheumatology (Oxford). 2005 Mar;44(3):280-6 [15657072.001]
  • [Cites] Ann Rheum Dis. 2005 Aug;64(8):1180-5 [15677700.001]
  • [Cites] Rheumatology (Oxford). 2005 Apr;44(4):547-52 [15695296.001]
  • [Cites] Rheumatology (Oxford). 2005 Jul;44(7):869-72 [15814578.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1063-8 [15818663.001]
  • [Cites] Arthritis Res Ther. 2005;7 Suppl 2:S4-14 [15833146.001]
  • [Cites] Curr Opin Rheumatol. 2005 May;17(3):299-304 [15838240.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):459-61 [15875058.001]
  • [Cites] Pharmacol Rev. 2005 Jun;57(2):163-72 [15914465.001]
  • [Cites] Genes Immun. 2005 Sep;6(6):467-71 [15931231.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1694-9 [15934099.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Rheumatology (Oxford). 2005 Oct;44(10):1263-6 [15998632.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1134-8 [16001646.001]
  • [Cites] Hum Genet. 2005 Oct;118(1):58-66 [16025348.001]
  • [Cites] Genes Immun. 2005 Dec;6(8):720-2 [16107870.001]
  • [Cites] Pediatr Nephrol. 2005 Nov;20(11):1566-71 [16133063.001]
  • [Cites] J Rheumatol. 2005 Sep;32(9):1650-3 [16142855.001]
  • [Cites] Rheumatol Int. 2006 Jun;26(8):726-31 [16220288.001]
  • [Cites] Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv2-14 [16239380.001]
  • [Cites] Exp Mol Pathol. 2006 Apr;80(2):141-6 [16248997.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3433-8 [16255021.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1317-9 [16273109.001]
  • [Cites] Arthritis Rheum. 2005 Dec;52(12):3813-8 [16320316.001]
  • [Cites] Am J Hum Genet. 2005 Dec;77(6):1044-60 [16380915.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):90-6 [16385500.001]
  • [Cites] Ann Rheum Dis. 2006 Sep;65(9):1213-8 [16439441.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):607-12 [16447238.001]
  • [Cites] Rheumatology (Oxford). 2006 Jul;45(7):804-7 [16449362.001]
  • [Cites] Arthritis Res Ther. 2006;8(2):R34 [16469113.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1087-95 [16572443.001]
  • [Cites] Arthritis Rheum. 2006 Apr;54(4):1117-21 [16572446.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R75 [16635271.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R79 [16646982.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R105 [16817978.001]
  • [Cites] Can J Physiol Pharmacol. 2006 Jan;84(1):15-20 [16845886.001]
  • [Cites] Eur J Clin Pharmacol. 2006 Nov;62(11):933-7 [16932953.001]
  • [Cites] Biomed Pharmacother. 2006 Dec;60(10):678-87 [17071051.001]
  • [Cites] Rheumatol Int. 2007 Jul;27(9):827-33 [17265154.001]
  • [Cites] Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40 [17343250.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):345-50 [17375096.001]
  • [Cites] J Immunol. 2007 Apr 15;178(8):4901-7 [17404271.001]
  • [Cites] Rheumatology (Oxford). 2007 Jun;46(6):1034-5 [17409133.001]
  • [Cites] Ann Rheum Dis. 2007 Nov;66(11):1525-30 [17456524.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):383-90 [17502830.001]
  • [Cites] Nat Rev Immunol. 2007 Jun;7(6):429-42 [17525752.001]
  • [Cites] Ann Intern Med. 2007 Jun 5;146(11):797-808 [17548411.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):661-78 [17554300.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):784-6 [17591062.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):358-63 [17666451.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):465-71 [17681167.001]
  • [Cites] N Engl J Med. 2007 Sep 20;357(12):1199-209 [17804836.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):977-86 [17804842.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4704-10 [17878369.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1431-3 [17982455.001]
  • [Cites] Nat Genet. 2007 Dec;39(12):1477-82 [17982456.001]
  • [Cites] Clin Exp Rheumatol. 2007 Sep-Oct;25(5):775-81 [18078632.001]
  • [Cites] J Hum Genet. 2008;53(2):163-73 [18087673.001]
  • [Cites] J Korean Med Sci. 2007 Dec;22(6):973-80 [18162709.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1663-9 [18250114.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):399-402 [18263596.001]
  • [Cites] Arthritis Res Ther. 2008;10(1):R26 [18307784.001]
  • [Cites] Mol Med. 2008 May-Jun;14(5-6):293-300 [18309376.001]
  • [Cites] Rheumatol Int. 2008 Jul;28(9):901-8 [18309487.001]
  • [Cites] Arthritis Res Ther. 2008;10(2):205 [18394179.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1211-5 [18438835.001]
  • [Cites] Arthritis Rheum. 2008 May;58(5):1275-83 [18438843.001]
  • [Cites] Arthritis Res Ther. 2008;10(3):R52 [18462498.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Sep;64(9):871-6 [18496682.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):1974-80 [18576336.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Nov;64(11):1057-68 [18607581.001]
  • [Cites] Hum Immunol. 2008 Sep;69(9):567-71 [18625278.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):898-903 [18633125.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):532-7 [18680473.001]
  • [Cites] Hum Mol Genet. 2008 Nov 15;17(22):3532-8 [18713756.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2598-602 [18759272.001]
  • [Cites] Ann Rheum Dis. 2009 Oct;68(10):1547-52 [18930989.001]
  • [Cites] Annu Rev Pathol. 2009;4:417-34 [18954286.001]
  • [Cites] Genes Immun. 2009 Mar;10(2):101-11 [18987647.001]
  • [Cites] Rheumatol Int. 2009 May;29(7):793-6 [19034456.001]
  • [Cites] Arthritis Rheum. 2009 Jan;60(1):30-8 [19116921.001]
  • [Cites] Pharmacogenomics. 2009 Feb;10(2):303-9 [19207032.001]
  • [Cites] J Rheumatol. 2009 Mar;36(3):539-45 [19208607.001]
  • [Cites] Arthritis Res Ther. 2009;11(2):R42 [19292917.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):244-50 [19342956.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):262-71 [19365266.001]
  • [Cites] Pharmacogenomics J. 2009 Jun;9(3):161-7 [19365401.001]
  • [Cites] Ann Rheum Dis. 2010 Mar;69(3):561-6 [19401279.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1255-60 [19404967.001]
  • [Cites] Hum Mol Genet. 2009 Jul 15;18(14):2693-9 [19417005.001]
  • [Cites] Immunol Rev. 2009 May;229(1):307-21 [19426230.001]
  • [Cites] Pharmacol Rep. 2009 Mar-Apr;61(2):281-7 [19443940.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R70 [19445664.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):666-70 [19470526.001]
  • [Cites] Mol Biol Rep. 2010 Jan;37(1):141-7 [19479340.001]
  • [Cites] Arthritis Res Ther. 2009;11(3):R99 [19563633.001]
  • [Cites] Arthritis Rheum. 2009 Sep;60(9):2577-84 [19714643.001]
  • [Cites] Nat Rev Rheumatol. 2009 Oct;5(10):531-41 [19798027.001]
  • [Cites] Cochrane Database Syst Rev. 2009;(4):CD007277 [19821401.001]
  • [Cites] Rheumatol Int. 2010 Mar;30(5):661-6 [19588142.001]
  • (PMID = 23226040.001).
  • [ISSN] 1178-7066
  • [Journal-full-title] Pharmacogenomics and personalized medicine
  • [ISO-abbreviation] Pharmgenomics Pers Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3513198
  • [Keywords] NOTNLM ; pharmacogenetics / rheumatoid arthritis / susceptibility genes
  •  go-up   go-down


3. Borm GF, Lemmers O, Fransen J, Donders R: The evidence provided by a single trial is less reliable than its statistical analysis suggests. J Clin Epidemiol; 2009 Jul;62(7):711-715.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When it is difficult to predict or determine how trial-specific factors influence the results, the best way to evaluate the performance of a treatment is to use multiple, possibly smaller, trials.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Data Interpretation, Statistical. Electromagnetic Fields / adverse effects. Humans. Leukemia, Radiation-Induced / epidemiology. Leukemia, Radiation-Induced / etiology. Outcome Assessment (Health Care) / methods. Patient Selection. Research Design

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Epidemiol. 2009 Aug;62(8):886-7; author reply 887-9 [19481419.001]
  • (PMID = 19171462.001).
  • [ISSN] 1878-5921
  • [Journal-full-title] Journal of clinical epidemiology
  • [ISO-abbreviation] J Clin Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  •  go-up   go-down


Advertisement
4. Starkebaum G: Chronic neutropenia associated with autoimmune disease. Semin Hematol; 2002 Apr;39(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic neutropenia with autoimmune diseases is associated mainly with rheumatoid arthritis (RA), as Felty's syndrome or large granular lymphocyte (LGL) leukemia, and with systemic lupus erythematosus (SLE).
  • Recent advances have allowed better understanding regarding the mechanism of neutropenia and improved options for treatment.
  • The role of soluble Fas-ligand (FasL) in inducing apoptosis of neutrophils has been clarified for LGL leukemia and increased neutrophil apoptosis has been described in neutropenic patients with SLE.
  • Treatments of neutropenia have included methotrexate, cyclosporine A, and granulocyte colony-stimulating factor (G-CSF) as well as granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • [MeSH-minor] Antibodies, Antineutrophil Cytoplasmic / immunology. Chronic Disease. Humans. Neutropenia / drug therapy. Neutropenia / etiology. Neutropenia / immunology. Neutrophils / drug effects. Neutrophils / immunology. Neutrophils / pathology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957195.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antineutrophil Cytoplasmic
  • [Number-of-references] 58
  •  go-up   go-down


5. Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia. Curr Hematol Malig Rep; 2007 Oct;2(4):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large granular lymphocyte leukemia.
  • Patients with symptomatic indolent T-cell or NK-cell LGL leukemia are usually treated with immunosuppressive therapies; in contrast, aggressive T-cell or NK-cell LGL leukemias require intensive chemotherapy regimens.
  • Novel targeted therapies are currently being tested in clinical studies.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Female. Humans. Immunophenotyping. Killer Cells, Natural / pathology. Leukemia, T-Cell / complications. Leukemia, T-Cell / epidemiology. Leukemia, T-Cell / immunology. Leukemia, T-Cell / pathology. Leukemia, T-Cell / therapy. Male. Middle Aged. Myelodysplastic Syndromes / pathology. Neutropenia / etiology. Opportunistic Infections / etiology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:63-79 [15561677.001]
  • [Cites] Am J Hematol. 2007 Jun;82(6):481-5 [17205534.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Cancer Control. 1998 Jan;5(1):25-33 [10761014.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):801-6 [11843812.001]
  • [Cites] Acta Haematol. 2000;104(2-3):110-4 [11154985.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):570-8 [16795070.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):201-12 [12876669.001]
  • [Cites] Am J Hematol. 1998 Nov;59(3):252-7 [9798667.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3000-6 [8639922.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Leuk Lymphoma. 1994 Jun;14(1-2):137-9 [7920220.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3352-3 [7538825.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):195-200 [11167802.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1207-11 [7630196.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1514-9 [8751472.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):598-600 [11849217.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):141-50 [17387299.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):241-50 [10439361.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):1010-4 [11843843.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):169-75 [3966754.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1282-5 [1831681.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2721-5 [7919384.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(2):105-11 [12621491.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2315-21 [7522625.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1969-71 [14976065.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2164-70 [7919331.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1474-83 [8608238.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] Arthritis Rheum. 1997 Apr;40(4):624-6 [9125243.001]
  • [Cites] Br J Haematol. 1993 Apr;83(4):589-94 [8100140.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • (PMID = 20425381.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 39
  •  go-up   go-down


6. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford); 2010 Feb;49(2):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m(2))] in addition to standard treatment, whereas six patients (control group) received standard treatment alone.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Immunosuppressive Agents / therapeutic use. Scleroderma, Systemic / drug therapy
  • [MeSH-minor] Adult. Aged. B-Lymphocytes / drug effects. Biopsy. Cell Adhesion Molecules / metabolism. Collagen / metabolism. Drug Administration Schedule. Humans. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lung Diseases, Interstitial / physiopathology. Lymphocyte Depletion / methods. Middle Aged. Respiratory Function Tests / methods. Rituximab. Skin / immunology. Skin / metabolism. Skin / pathology. Tomography, X-Ray Computed. Vital Capacity / drug effects

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 1991 Oct;18(10):1520-8 [1765976.001]
  • [Cites] Arch Intern Med. 1993 Jun 14;153(11):1337-42 [8507124.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):559-62 [9492775.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):220 [10421308.001]
  • [Cites] Arthritis Rheum. 2005 Feb;52(2):501-13 [15693003.001]
  • [Cites] J Rheumatol. 2005 May;32(5):832-40 [15868618.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4885-91 [15746077.001]
  • [Cites] Curr Opin Rheumatol. 2005 Nov;17(6):746-51 [16224253.001]
  • [Cites] Transplantation. 2006 Feb 27;81(4):573-82 [16495806.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Drugs. 2006;66(8):1041-57 [16789791.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2655-66 [16790698.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2667-76 [16790699.001]
  • [Cites] Blood. 2006 Jul 15;108(2):756-62 [16551963.001]
  • [Cites] Rheumatology (Oxford). 2006 Aug;45(8):1005-8 [16490756.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):954-66 [16936269.001]
  • [Cites] Rheumatology (Oxford). 2006 Dec;45(12):1572 [16998235.001]
  • [Cites] Ann Rheum Dis. 2003 Sep;62(9):904-5 [12922969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12319-24 [14530402.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1721-33 [15188347.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1918-27 [15188368.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):641-50 [15277237.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Mol Immunol. 2004 Nov;41(12):1123-33 [15482848.001]
  • [Cites] Arthritis Rheum. 1980 May;23(5):581-90 [7378088.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85 [17133253.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3962-70 [17133610.001]
  • [Cites] Rheumatol Int. 2007 Feb;27(4):357-61 [17021713.001]
  • [Cites] Rheumatology (Oxford). 2007 Mar;46(3):442-5 [16899504.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):66-73 [17275413.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Jun;20(2):349-60 [17448966.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):623-4 [17454609.001]
  • [Cites] Ann Rheum Dis. 2007 Jul;66(7):966-9 [17234649.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1388-96 [17452515.001]
  • [Cites] Arthritis Rheum. 2007 Sep;56(9):3167-8 [17763433.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34 [17717203.001]
  • [Cites] Nephrology (Carlton). 2007 Dec;12(6):553-8 [17995580.001]
  • [Cites] Rheumatology (Oxford). 2008 Apr;47(4):552-3 [18281368.001]
  • [Cites] Arthritis Rheum. 2009 Feb;60(2):578-83 [19180481.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):193-7 [19103636.001]
  • [Cites] Arthritis Care Res. 1991 Mar;4(1):27-31 [11188583.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):329-34 [11759059.001]
  • [CommentIn] Rheumatology (Oxford). 2010 Feb;49(2):201-2 [20032221.001]
  • (PMID = 19447770.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cell Adhesion Molecules; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ PMC2806066
  •  go-up   go-down


7. Biswas S, Keddington J, McClanathan J: Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture; a case report and review of relevant literature. World J Emerg Surg; 2006;1:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Spontaneous rupture of the spleen is an uncommon dramatic abdominal emergency that requires immediate diagnosis and prompt surgical treatment to ensure the patients survival.
  • Acute leukemia and non Hodgkin lymphoma were the frequent causes followed by chronic myelogenous leukemia.
  • Male sex, adulthood, severe splenomegaly and cytoreductive chemotherapy were factors more often associated with splenic rupture.
  • Emergency splenectomy remains the cornerstone treatment for splenic rupture.
  • We present a case report of a "spontaneous splenic rupture" and discuss the presentation, etiology and treatment options along with discussion of relevant literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1996 May;83(5):632 [8689204.001]
  • [Cites] Pathology. 1994 Oct;26(4):493-6 [7892057.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):631-5 [7863884.001]
  • [Cites] Cancer. 1981 Dec 15;48(12):2729-33 [7306928.001]
  • [Cites] Am J Clin Pathol. 1984 Jul;82(1):104-9 [6234792.001]
  • [Cites] Mich Med. 1966 Feb;65(2):105-10 [5901949.001]
  • [Cites] Arch Surg. 1972 May;104(5):652-7 [4503094.001]
  • [Cites] Am J Emerg Med. 1989 Jan;7(1):28-31 [2643958.001]
  • [Cites] Acta Haematol. 2005;113(4):255-7 [15983432.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):131-5 [14508801.001]
  • [Cites] Int Abstr Surg. 1958 Jan;106(1):1-11 [13495867.001]
  • [Cites] Lupus. 2001;10(12):876-8 [11787878.001]
  • [Cites] J Pediatr Surg. 1999 Mar;34(3):498-9 [10211667.001]
  • [Cites] Eur J Surg. 1999 Jul;165(7):712-3 [10452269.001]
  • [Cites] Ann Hematol. 2000 Mar;79(3):158-60 [10803939.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8 [11298158.001]
  • [Cites] Clin Infect Dis. 1993 Feb;16(2):223-32 [8443301.001]
  • [Cites] Radiographics. 1994 Mar;14(2):307-32 [8190956.001]
  • [Cites] Ann Hematol. 1996 Dec;73(6):297-302 [9003161.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):336-7 [9332543.001]
  • [Cites] Semin Arthritis Rheum. 1997 Dec;27(3):141-55 [9431585.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):276-8 [9934775.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):89-93 [9022775.001]
  • (PMID = 17129392.001).
  • [ISSN] 1749-7922
  • [Journal-full-title] World journal of emergency surgery : WJES
  • [ISO-abbreviation] World J Emerg Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1712221
  •  go-up   go-down


8. Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W: Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis; 2001 Sep;60(9):892-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.
  • A 55 year old man with chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis (RA), treated for four years with methotrexate (MTX), who developed a B cell non-Hodgkin's lymphoma (B-NHL), is described.
  • After failure of radiation and chemotherapy, a complete remission was achieved with a combination of antibody treatment (rituximab) and EPOCH.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Lymphoma, B-Cell / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunocompromised Host. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male. Middle Aged. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / etiology. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11502618.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1753822
  •  go-up   go-down


9. Asano Y, Bujor AM, Trojanowska M: The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci; 2010 Sep;59(3):153-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic sclerosis (SSc) is an autoimmune inflammatory disease with unknown etiology characterized by microvascular injury and fibrosis of the skin and internal organs.
  • A growing body of evidence suggests that deficiency of the transcription factor Fli1 (Friend leukemia integration-1) has a pivotal role in the pathogenesis of SSc.
  • In this article, we review the impact of Fli1 deficiency on the pathogenesis of SSc and discuss a new therapeutic strategy for SSc by targeting the transcription factor Fli1.
  • [MeSH-major] Proto-Oncogene Protein c-fli-1 / metabolism. Scleroderma, Systemic / drug therapy. Scleroderma, Systemic / enzymology
  • [MeSH-minor] Acetylation / drug effects. Animals. Autoimmune Diseases / drug therapy. B-Lymphocytes / drug effects. Benzamides. Collagen Type I / antagonists & inhibitors. Down-Regulation. Drug Therapy, Combination. Epigenesis, Genetic. Extracellular Matrix / drug effects. Fibroblasts / drug effects. Gene Expression / drug effects. Hematopoiesis / drug effects. Humans. Imatinib Mesylate. Macrolides / pharmacology. Mice. Phosphorylation / drug effects. Piperazines / pharmacology. Piperazines / therapeutic use. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Processing, Post-Translational / drug effects. Pyrimidines / pharmacology. Pyrimidines / therapeutic use. T-Lymphocytes / drug effects

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Gastroenterology. 2006 Oct;131(4):1235-52 [17030193.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):39870-80 [17074756.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):500-8 [16862174.001]
  • [Cites] Arthritis Rheum. 2007 Jan;56(1):311-22 [17195235.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1694-705 [17469184.001]
  • [Cites] Br J Haematol. 2007 Jul;138(1):12-30 [17555444.001]
  • [Cites] Clin Biochem. 2007 Aug;40(12):837-42 [17493602.001]
  • [Cites] J Dermatol Sci. 2007 Sep;47(3):217-26 [17601707.001]
  • [Cites] Arthritis Rheum. 2007 Aug;56(8):2747-54 [17665441.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 2:S5 [17767743.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34672-83 [17884818.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Dec 15;176(12):1243-50 [17717205.001]
  • [Cites] J Dermatol. 2008 Feb;35(2):63-9 [18271800.001]
  • [Cites] Rheum Dis Clin North Am. 2008 Feb;34(1):115-43; vii [18329536.001]
  • [Cites] Future Oncol. 2008 Apr;4(2):211-7 [18407734.001]
  • [Cites] Rheumatology (Oxford). 2008 May;47(5):735-7 [18326532.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jul 1;178(1):81-8 [18420966.001]
  • [Cites] FASEB J. 2008 Jul;22(7):2214-22 [18326784.001]
  • [Cites] Rheumatology (Oxford). 2008 Aug;47(8):1239-43 [18559373.001]
  • [Cites] J Immunol. 2008 Aug 1;181(3):1644-54 [18641300.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2528-37 [18668566.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2549-52 [18668570.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20839-48 [11278621.001]
  • [Cites] Leuk Res. 2001 Sep;25(9):821-5 [11489476.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1395-403 [11696585.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):123-7 [12379474.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):571-81 [12875977.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):253-64 [14722617.001]
  • [Cites] J Cell Biochem. 2004 Apr 1;91(5):896-903 [15034925.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1275-92 [15039216.001]
  • [Cites] Cancer. 2004 May 15;100(10):2064-78 [15139047.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):7123-35 [15153536.001]
  • [Cites] Genes Dev. 2004 Aug 1;18(15):1824-37 [15289456.001]
  • [Cites] Nucleic Acids Res. 2004;32(18):5693-702 [15498926.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):59-66 [5009623.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2543-8 [18668587.001]
  • [Cites] Clin Immunol. 2008 Oct;129(1):19-30 [18692443.001]
  • [Cites] Arch Dermatol. 2008 Sep;144(9):1106-9 [18794453.001]
  • [Cites] Rheumatology (Oxford). 2009 Jan;48(1):49-52 [18815156.001]
  • [Cites] Bone Marrow Transplant. 2008 Dec;42(11):757-60 [18762765.001]
  • [Cites] Mol Cell Biol. 2009 Jan;29(2):425-34 [19001092.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1882-94 [19158279.001]
  • [Cites] Oncogene. 2009 Mar 12;28(10):1285-97 [19151753.001]
  • [Cites] Clin Res Cardiol. 2009 Apr;98(4):265-7 [19219392.001]
  • [Cites] Nat Rev Rheumatol. 2009 Apr;5(4):200-6 [19337284.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1043-63, vi [19825452.001]
  • [Cites] Recent Results Cancer Res. 2010;184:3-20 [20072827.001]
  • [Cites] Curr Opin Rheumatol. 2010 Mar;22(2):133-8 [20090527.001]
  • [Cites] Mayo Clin Proc. 2010 Feb;85(2):158-64 [20053713.001]
  • [Cites] Arthritis Rheum. 2010 Mar;62(3):878-89 [20131241.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1983-98 [20228226.001]
  • [Cites] Curr Biol. 2008 Aug 26;18(16):1234-40 [18718762.001]
  • [Cites] Clin Rheumatol. 2000;19(2):165-6 [10791633.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5643-52 [10891501.001]
  • [Cites] Immunity. 2000 Aug;13(2):167-77 [10981960.001]
  • [Cites] Nucleic Acids Res. 2000 Nov 1;28(21):4291-8 [11058129.001]
  • [Cites] Arthritis Rheum. 2001 Feb;44(2):474-80 [11229480.001]
  • [Cites] J Clin Invest. 1974 Oct;54(4):880-9 [4430718.001]
  • [Cites] Arthritis Rheum. 1978 May;21(4):418-28 [350229.001]
  • [Cites] Genes Dev. 1991 Jun;5(6):908-18 [2044959.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] J Biol Chem. 1994 Jul 8;269(27):18216-22 [7517940.001]
  • [Cites] Am J Hum Genet. 1995 Mar;56(3):676-83 [7887422.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1805-14 [7703487.001]
  • [Cites] J Invest Dermatol. 1995 Aug;105(2):280-4 [7636314.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6961-70 [8524263.001]
  • [Cites] Int J Cancer. 1995 Nov 15;63(4):500-4 [7591257.001]
  • [Cites] Genome Res. 1999 Jan;9(1):44-52 [9927483.001]
  • [Cites] J Cell Physiol. 1999 Oct;181(1):153-9 [10457363.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1308-16 [15520863.001]
  • [Cites] Nature. 1964 May 16;202:708-9 [14190049.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):6481-9 [15528390.001]
  • [Cites] Blood. 2005 Jan 1;105(1):95-102 [15367440.001]
  • [Cites] FASEB J. 2005 Jan;19(1):1-11 [15629889.001]
  • [Cites] J Invest Dermatol. 2005 Feb;124(2):324-30 [15675950.001]
  • [Cites] Vitam Horm. 2005;70:69-103 [15727802.001]
  • [Cites] J Biochem. 2005 Mar;137(3):297-302 [15809330.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1237-47 [15818662.001]
  • [Cites] Exp Hematol. 2005 May;33(5):550-7 [15850832.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1451-63 [15855645.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):886-92 [15854026.001]
  • [Cites] Rheumatology (Oxford). 2005 Jun;44(6):824-6 [15769789.001]
  • [Cites] Nucleic Acids Res. 2005;33(11):3540-9 [15972796.001]
  • [Cites] Arthritis Rheum. 2005 Sep;52(9):2897-905 [16142753.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] N Engl J Med. 2005 Sep 29;353(13):1412-3 [16192491.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2811-21 [16200212.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7708-18 [16301681.001]
  • [Cites] Rheumatology (Oxford). 2006 Feb;45(2):157-65 [16319104.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):499-510 [16436664.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 12;343(3):904-9 [16564026.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2547-52 [16631755.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1761-9 [16675963.001]
  • [Cites] Ann Intern Med. 2006 Jul 18;145(2):152-3 [16847299.001]
  • [Cites] Arthritis Rheum. 2006 Jul;54(7):2271-9 [16802366.001]
  • [Cites] J Biol Chem. 2006 Sep 1;281(35):25259-69 [16829517.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):717-8 [17001803.001]
  • (PMID = 20663647.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR042334
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Collagen Type I; 0 / FLI1 protein, human; 0 / Macrolides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Protein c-fli-1; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ NIHMS525829; NLM/ PMC3826615
  •  go-up   go-down


10. Bowman SJ: Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol; 2002;31(5):251-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematological manifestations of rheumatoid arthritis.
  • OBJECTIVE: To inform clinical rheumatologists about the common and rarer hematological manifestations of rheumatoid arthritis with an emphasis on diagnosis and therapy and a particular reference to Felty's syndrome.
  • RESULTS: The hematological manifestations can be conveniently categorized into the broad areas of; anemia, particularly NSAID induced iron deficiency anemia and the anemia of chronic disease, neutropenia, particularly Felty's syndrome and the large granular lymphocyte syndrome and drug induced neutropenia; thrombocytopenia, particularly autoimmune and drug induced thrombocytopenia; and hematological malignancy.
  • Rarer conditions, their diagnosis and therapy are also described in this review.
  • CONCLUSION: Hematological manifestations of rheumatoid arthritis are very common.
  • A logical approach using easily available tests should allow straightforward decisions about diagnosis and therapy to be made, even in patients with some of the rarer manifestations.
  • [MeSH-major] Arthritis, Rheumatoid. Hematologic Diseases
  • [MeSH-minor] Anemia / etiology. Blood Platelet Disorders / etiology. Databases, Bibliographic. Felty Syndrome / blood. Felty Syndrome / complications. Felty Syndrome / diagnosis. Humans. Immunocompromised Host. Leukemia, Lymphoid / blood. Leukemia, Lymphoid / complications. Leukemia, Lymphoid / diagnosis. Lymphoma / etiology


11. Hu RQ, Mehter H, Nadasdy T, Satoskar A, Spetie DN, Rovin BH, Hebert L: Severe hemorrhagic cystitis associated with prolonged oral cyclophosphamide therapy: case report and literature review. Rheumatol Int; 2008 Sep;28(11):1161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hemorrhagic cystitis associated with prolonged oral cyclophosphamide therapy: case report and literature review.
  • Severe hemorrhagic cystitis associated with oral cyclophosphamide (CYP) therapy has rarely been reported in the past 20 years, probably because this condition has largely disappeared because of the use of shorter courses of CYP, either oral or IV.
  • She came under our care for the first time when she presented with a one-day history of oliguria and passing blood clots.
  • She survived her acute illness only to die 2 months later of acute leukemia.
  • Alternative therapies are discussed.
  • [MeSH-minor] Blood Transfusion. Fatal Outcome. Female. Glomerulonephritis / etiology. Granulomatosis with Polyangiitis / drug therapy. Hematuria / etiology. Hemorrhage / therapy. Humans. Middle Aged

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 1970;25(2):187-95 [5422716.001]
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2836-40 [11762944.001]
  • [Cites] Am J Kidney Dis. 2003 Dec;42(6):1149-53 [14655185.001]
  • [Cites] Kidney Int. 2004 Apr;65(4):1440-8 [15086487.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):899-901 [11081392.001]
  • [Cites] N Y State J Med. 1969 Jan 15;69(2):305-9 [5251301.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):451-7 [3338015.001]
  • [Cites] J Am Soc Nephrol. 1999 Sep;10 (9):1965-71 [10477149.001]
  • [Cites] Arthritis Res Ther. 2003;5(4):180-91 [12823849.001]
  • [Cites] Arthritis Rheum. 1988 Apr;31(4):465-70 [3358809.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):575 [12406105.001]
  • [Cites] Br J Urol. 1973 Dec;45(6):606-9 [4775738.001]
  • [Cites] J Urol. 1974 May;111(5):603-6 [4856785.001]
  • [Cites] J Intern Med. 2005 Jun;257(6):540-8 [15910558.001]
  • [Cites] JAMA. 1973 Aug 6;225(6):605-6 [4740525.001]
  • [Cites] Nephrol Dial Transplant. 2001 Oct;16(10):2018-27 [11572891.001]
  • [Cites] Transplantation. 2000 Dec 27;70(12):1807-11 [11152115.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1405-13 [11230485.001]
  • (PMID = 18398616.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 19
  •  go-up   go-down


12. Westhoff B, J├Ąger M, Krauspe R: [Osteonecrosis after chemotherapy in children]. Orthopade; 2008 Jan;37(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteonecrosis after chemotherapy in children].
  • [Transliterated title] Osteonekrosen nach Chemotherapie im Kindesalter.
  • The application of modern chemotherapy protocols has improved healing and survival rates significantly in pediatric malignancies.
  • As a result, the long-term drug-related side effects are becoming increasingly apparent.
  • Avascular osteonecrosis (AVN) occurs in up to 40% of all patients who have undergone chemotherapy, the average time of onset being 12-18 months after chemotherapy.
  • Typical risk factors for AVN after chemotherapy are the application of glucocorticoids and an age of 10 ys. and older.
  • The etiology remains unclear.
  • Evidence-based, standardized therapeutic concepts or orthopedic guidelines are not available for these patients to date.
  • The range of treatment options includes several operative and non-operative treatment alternatives.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Drug-Related Side Effects and Adverse Reactions. Osteonecrosis / chemically induced
  • [MeSH-minor] Adolescent. Age Factors. Arthrodesis. Arthroplasty, Replacement. Bone Density Conservation Agents / therapeutic use. Bone Transplantation. Child. Diagnosis, Differential. Diphosphonates / therapeutic use. Female. Humans. Hyperbaric Oxygenation. Magnetic Resonance Imaging. Male. Orthopedic Procedures. Radiography. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomed Tech (Berl). 2006 Dec;51(5-6):371-6 [17155875.001]
  • [Cites] Am J Transplant. 2007 Mar;7(3):667-71 [17217441.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Feb;19(2):161-7 [16562590.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1430-7 [15995108.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):370-8 [15565553.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3262-72 [10986059.001]
  • [Cites] Eur Radiol. 1997;7(2):180-6 [9038111.001]
  • [Cites] J Bone Joint Surg Am. 2006 Dec;88(12):2565-72 [17142405.001]
  • [Cites] J Bone Joint Surg Br. 1986 May;68(3):414-7 [3525571.001]
  • [Cites] Ann Pharmacother. 2007 Feb;41(2):276-84 [17299010.001]
  • [Cites] Clin Orthop Relat Res. 2006 Feb;443:273-9 [16462451.001]
  • [Cites] Clin Orthop Relat Res. 2002 Dec;(405):14-23 [12461352.001]
  • [Cites] Clin Radiol. 1997 Aug;52(8):607-12 [9285421.001]
  • [Cites] Leukemia. 2001 Jun;15(6):891-7 [11417473.001]
  • [Cites] Radiol Clin North Am. 1986 Jun;24(2):193-208 [3714996.001]
  • [Cites] Arthritis Rheum. 1970 Jul-Aug;13(4):445-7 [5429644.001]
  • [Cites] Med Pediatr Oncol. 1993;21(9):655-60 [8412999.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1717-21 [2317754.001]
  • [Cites] Pediatr Radiol. 1990;20(4):272-6 [2336289.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1997 Sep-Oct;135(5):444-50 [9446438.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):11-7 [9917747.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 2004 Mar-Apr;142(2):194-212 [15106066.001]
  • [Cites] Int J Hyperthermia. 2006 Sep;22(6):451-61 [16971366.001]
  • [Cites] J Bone Joint Surg Br. 2005 Jul;87(7):896-902 [15972899.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2407-12 [8635114.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Jul-Aug;15(4):307-15 [9658431.001]
  • [Cites] Klin Padiatr. 2003 Nov-Dec;215(6):332-7 [14677098.001]
  • [Cites] J Pediatr Orthop. 2000 May-Jun;20(3):331-5 [10823600.001]
  • [Cites] Rofo. 2000 Apr;172(4):336-41 [10961217.001]
  • [Cites] Eur J Pediatr. 1989 Dec;149(3):162-3 [2612502.001]
  • [Cites] J Bone Joint Surg Br. 2007 Jan;89(1):127-9 [17259431.001]
  • [Cites] Schmerz. 2004 Dec;18(6):481-91 [15293153.001]
  • (PMID = 18210081.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


13. Edwards SA, Cranfield T, Clarke HJ: Atypical presentation of septic arthritis in the immunosuppressed patient. Orthopedics; 2002 Oct;25(10):1089-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of septic arthritis in the immunosuppressed patient.
  • [MeSH-major] Arthritis, Infectious / diagnosis. Escherichia coli Infections / diagnosis. Hip Joint
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Diagnosis, Differential. Drainage / methods. Drug-Related Side Effects and Adverse Reactions. Humans. Leukemia, T-Cell / drug therapy. Male. Pancytopenia / etiology. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12401018.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


14. Singh YP, Agarwal V, Krishnani N, Misra R: Enthesitis-related arthritis in Kikuchi-Fujimoto disease. Mod Rheumatol; 2008;18(5):492-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enthesitis-related arthritis in Kikuchi-Fujimoto disease.
  • Articular manifestations in the form of arthralgias are common but frank arthritis is distinctly rare and dactylitis has not been reported yet.
  • Herein, we describe a young boy who presented with arthritis and dactylitis as the initial manifestation of KFD.
  • Two years earlier he presented with arthritis of the knee and ankle joints, which lasted for 12 months.
  • Work-up for infectious etiology, systemic lupus erythematosus and leukemia and lymphoma was negative.
  • Fever, lymphadenopathy and leukopenia dissipated with nonsteroidal anti inflammatory drug therapy, but the arthritis persisted.
  • A trial of methotrexate led to the resolution of the arthritis.

  • Genetic Alliance. consumer health - Kikuchi disease.
  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18470474.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hayashi T, Nozaki M, Nonaka Y, Ohashi K, Sakamaki H, Nomura T: Pyomyositis as a focus of infection in hematological disorders: a report of 3 cases. Int J Hematol; 2003 Feb;77(2):171-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 40-year-old man in the blastic phase of chronic myelogenous leukemia and 2 men aged 46 and 71 years with neutropenia due to myelodysplastic syndromes all reported high fever and severe local myalgia and had marked elevation of C-reactive protein.
  • [MeSH-minor] Adult. Aged. Drug Resistance, Bacterial. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Methicillin. Middle Aged. Neutropenia. Opportunistic Infections / diagnosis. Opportunistic Infections / drug therapy. Staphylococcal Infections / diagnosis. Staphylococcal Infections / drug therapy. Staphylococcal Infections / etiology. Staphylococcus aureus

  • Genetic Alliance. consumer health - Pyomyositis.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Myositis.
  • Hazardous Substances Data Bank. METHICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Baillieres Clin Rheumatol. 1995 Feb;9(1):193-200 [7728881.001]
  • [Cites] J Microbiol Immunol Infect. 2002 Jun;35(2):121-4 [12099333.001]
  • [Cites] Radiology. 1995 Oct;197(1):279-86 [7568838.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):275-8 [2609386.001]
  • [Cites] Lancet. 1983 Nov 26;2(8361):1240-2 [6139580.001]
  • [Cites] BMJ. 1989 Aug 5;299(6695):375-6 [2506973.001]
  • [Cites] Am J Surg. 1979 Feb;137(2):255-9 [426186.001]
  • [Cites] Clin Infect Dis. 1992 Oct;15(4):668-77 [1420680.001]
  • [Cites] Semin Arthritis Rheum. 1994 Jun;23(6):396-405 [7939725.001]
  • (PMID = 12627853.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q91FH1328A / Methicillin
  •  go-up   go-down


16. Kumana CR: Aspects of general medicine. Hong Kong Med J; 2008 Oct;14(5):385-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The chapters summarised include: Contemporary management of acute myocardial infarction; Imported infectious disease emergencies; New therapies in the management of type 2 diabetes; Stress and adrenal insufficiency; Making sense of a 'funny thyroid function test'; Myeloproliferative disorders: management and molecular pathogenesis; Drug allergies; Osteoporosis; Rheumatoid arthritis; Understanding migraine from bench to bedside.

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840910.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 2
  •  go-up   go-down


17. Sakata N, Yasui M, Kawa K: Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation. Int J Hematol; 2001 Jul;74(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pneumococcal arthritis affects performance status in patients with chronic GVHD of the skin following allogeneic bone marrow transplantation.
  • We encountered 2 patients with pneumococcal arthritis following bone marrow transplantation (BMT).
  • Twenty-four months after BMT and 7 months after the onset of EB-LPD, pneumococcal arthritis occurred in both knee joints.
  • The other patient, a 10-year-old girl, received multiagent immunosuppressive therapy for her chronic GVHD.
  • At 51 months following BMT, pneumococcal arthritis occurred in her left knee joint.
  • Chronic GVHD of the skin delayed the recovery from the arthritis in both patients.
  • Although vaccination against pneumococcus or preventive antibiotics should be administered to high-risk patients, early diagnosis and treatment may be the best strategy for pneumococcal arthritis.
  • [MeSH-major] Arthritis, Infectious / etiology. Bone Marrow Transplantation / adverse effects. Cross Infection / etiology. Graft vs Host Disease / etiology. Leukemia, Myelomonocytic, Acute / therapy. Pneumococcal Infections / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Skin / pathology
  • [MeSH-minor] Anti-Bacterial Agents. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Drug Therapy, Combination / therapeutic use. Epstein-Barr Virus Infections / etiology. Female. Humans. Immunocompromised Host. Knee Joint. Lymphoproliferative Disorders / etiology. Lymphoproliferative Disorders / virology. Male. Severity of Illness Index. Transplantation, Homologous / adverse effects


18. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood; 2006 Jul 15;108(2):756-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore designed a phase 1/2 study of anti-B-cell therapy with rituximab in steroid-refractory chronic GVHD.
  • Responses were limited to patients with cutaneous and musculoskeletal manifestations of chronic GVHD and were durable through 1 year after therapy.
  • The median dose of prednisone among treated subjects fell from 40 mg/day to 10 mg/day, 1 year after rituximab therapy (P < .001).
  • Antibody titers against Y chromosome-encoded minor HLA antigens fell and remained low, whereas titers against infectious antigens (EBV, tetanus) remained stable or rose during the treatment period.
  • We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Drug Resistance. Graft vs Host Disease / drug therapy. Steroids / pharmacology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Chronic Disease. Female. Humans. Male. Middle Aged. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / etiology. Prednisone / pharmacology. Rituximab. Salvage Therapy / methods. Skin Diseases / drug therapy. Skin Diseases / etiology

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):353-9 [14512314.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1502-5 [10666232.001]
  • [Cites] Ann Intern Med. 2000 Aug 15;133(4):275-9 [10929168.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3995-6 [11090092.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1196-201 [11222360.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(5):265-73 [11400948.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):121-9 [11509929.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3595-9 [11739162.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3868-70 [11739201.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2712-9 [11929757.001]
  • [Cites] Br J Haematol. 2002 Jun;117(3):771-3 [12028061.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(8):444-52 [12234170.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:113-6 [10707791.001]
  • [Cites] Leukemia. 2006 Jan;20(1):172-3 [16239908.001]
  • [Cites] Clin Immunol. 2005 Dec;117(3):207-13 [16169773.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3308-13 [16046530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Jun;99(6):696-703 [15897856.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2973-8 [15613541.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3580-90 [15529346.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(8):735-41 [9827969.001]
  • [Cites] Blood. 2002 Jul 1;100(1):48-51 [12070007.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4364-9 [12036863.001]
  • [Cites] Haematologica. 2003 Mar;88(3):315-23 [12651271.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Feb;12(1):9-10 [12662431.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(11):1023-5 [12774054.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):457-64 [12877674.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Aug;9(8):505-11 [12931119.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1253-8 [10642818.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):28-35 [14725898.001]
  • [Cites] J Exp Med. 2004 Apr 19;199(8):1133-42 [15096539.001]
  • [Cites] Curr Opin Rheumatol. 2004 May;16(3):180-5 [15103242.001]
  • [Cites] Br J Haematol. 2004 May;125(4):435-54 [15142114.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2603-6 [15251978.001]
  • [Cites] Blood. 1996 Jan 15;87(2):818-26 [8555508.001]
  • [Cites] Bone Marrow Transplant. 1997 Jun;19(11):1129-36 [9193757.001]
  • (PMID = 16551963.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00136396
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Steroids; 4F4X42SYQ6 / Rituximab; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC1895490
  •  go-up   go-down


19. Balakrishnan C, Pathan E, Khodaiji S, Dasgupta A, Mangat G, Joshi VR: Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil. J Assoc Physicians India; 2004 May;52:423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
  • Immunosuppressive therapy related secondary haematologic malignancy is well reported.
  • A 52 years lady with established rheumatoid arthritis developed reactive amyloidosis.
  • Ten months after stopping chlorambucil she developed pancytopenia and vitamin B12 deficient megaloblastic anaemia.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Chlorambucil / adverse effects. Leukemia, Myeloid / chemically induced. Myelodysplastic Syndromes / chemically induced
  • [MeSH-minor] Acute Disease. Amyloidosis / drug therapy. Amyloidosis / etiology. Fatal Outcome. Female. Humans. Kidney Diseases / drug therapy. Kidney Diseases / etiology. Middle Aged


20. Turgut B, Vural O, Demir M, Kaldir M: Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B. Ann Hematol; 2002 Sep;81(9):529-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B.
  • Candida arthritis is quite rare and might be caused either by direct intra-articular inoculation of Candida or secondary to hematogeneous seeding of Candida in immunocompromised hosts.
  • Until now less than 50 cases of Candida arthritis have been reported in the literature.
  • We report a case of Candida arthritis, which occurred in a patient with chronic myelogenous leukemia (CML) in blastic transformation.
  • Aggressive chemotherapy and broad-spectrum antibiotics for a prolonged period for febrile neutropenia had been given to the patient.
  • Arthritis of the left knee appeared during the recovery phase of leukopenia.
  • Despite treatment with fluconazole, no clinical or microbiological improvement was obtained.
  • We can conclude that fluconazole might not be sufficient in some Candida arthritis cases and liposomal amphotericin B might be a good alternative in these resistant cases.
  • [MeSH-major] Amphotericin B / administration & dosage. Arthritis, Infectious / drug therapy. Candidiasis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Phosphatidylcholines / administration & dosage. Phosphatidylglycerols / administration & dosage
  • [MeSH-minor] Blast Crisis. Drug Combinations. Drug Resistance. Fatal Outcome. Female. Fluconazole / administration & dosage. Humans. Middle Aged. Opportunistic Infections / drug therapy. Opportunistic Infections / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12373355.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Phosphatidylcholines; 0 / Phosphatidylglycerols; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


21. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC, Children's Oncology Group Pilot Study: Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol; 2008 Aug 1;26(22):3756-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
  • PURPOSE: To determine the tolerability and serum concentration of epratuzumab, a humanized monoclonal antibody targeting CD22, administered alone and in combination with reinduction chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL), and to preliminarily assess tumor targeting and efficacy.
  • PATIENTS AND METHODS: Therapy consisted of a single-agent phase (epratuzumab 360 mg/m(2)/dose intravenously twice weekly x four doses), followed by four weekly doses of epratuzumab in combination with standard reinduction chemotherapy.
  • Two dose-limiting toxicities occurred: one grade 4 seizure of unclear etiology and one asymptomatic grade 3 ALT elevation.
  • In all but one patient, surface CD22 was not detected by flow cytometry on peripheral blood leukemic blasts within 24 hours of drug administration, indicating effective targeting of leukemic cells by epratuzumab.
  • CONCLUSION: Treatment with epratuzumab plus standard reinduction chemotherapy is feasible and acceptably tolerated in children with relapsed CD22-positive ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Oct;17(10):1967-72 [14513046.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3971-8 [18711187.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Cancer Immunol Immunother. 1993 Oct;37(5):293-8 [7691407.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):538-45 [8112889.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S [14506197.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Annu Rev Immunol. 1997;15:481-504 [9143697.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4846-50 [15570088.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2826-32 [17099879.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R129 [16859536.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3704-13 [17530024.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • (PMID = 18669463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / CD22 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  • [Other-IDs] NLM/ PMC2654811
  •  go-up   go-down


22. Stamp L, Searle M, O'Donnell J, Chapman P: Gout in solid organ transplantation: a challenging clinical problem. Drugs; 2005;65(18):2593-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In transplant recipients, therapy with ciclosporin (cyclosporin) is an additional risk factor.
  • Hyperuricaemia is recognised as an independent risk factor for cardiovascular disease; however, whether anti-hyperuricaemic therapy reduces cardiovascular events remains to be determined.
  • While gout is curable, its pharmacological management in transplant recipients is complicated by the risk of adverse effects and potentially severe interactions between immunosuppressive and hypouricaemic drugs.
  • Long-term urate-lowering therapy is required to promote dissolution of uric acid crystals, thereby preventing recurrent attacks of gout.
  • Physicians should carefully consider therapeutic options for the management of hypertension and hyperlipidaemia, which are common in transplant recipients.
  • Recognition and, if possible, alleviation of risk factors, prompt treatment of acute attacks and early introduction of hypouricaemic therapy with careful monitoring are the keys to successful management.
  • [MeSH-major] Gout / etiology. Gout / therapy. Organ Transplantation / adverse effects
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diet. Drug Interactions. Glucocorticoids / therapeutic use. Gout Suppressants / therapeutic use. Health Behavior. Humans. Hyperuricemia / etiology. Hyperuricemia / physiopathology. Immunosuppressive Agents / adverse effects. Patient Education as Topic. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Gout.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Kidney Dis. 1996 May;27(5):701-8 [8629631.001]
  • [Cites] Nephrol Dial Transplant. 1997 Nov;12(11):2389-92 [9394328.001]
  • [Cites] Semin Hematol. 2001 Oct;38(4 Suppl 10):13-21 [11694947.001]
  • [Cites] J Hepatol. 2000 May;32(5):874 [10845680.001]
  • [Cites] Hypertension. 1995 Jul;26(1):112-7 [7607713.001]
  • [Cites] Arthritis Rheum. 2003 Aug;48(8):2310-20 [12905486.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2273-80 [15248227.001]
  • [Cites] Am J Med. 1984 Jan;76(1):47-56 [6691361.001]
  • [Cites] Am J Transplant. 2002 May;2(5):436-42 [12123209.001]
  • [Cites] Clin Sci (Lond). 1986 May;70(5):501-5 [3516534.001]
  • [Cites] Scand J Rheumatol. 1996;25(2):105-6 [8614764.001]
  • [Cites] J Rheumatol. 1994 Apr;21(4):710-3 [8035398.001]
  • [Cites] Am J Med. 1987 Mar;82(3):421-6 [3826098.001]
  • [Cites] Arthritis Rheum. 1991 Feb;34(2):141-5 [1994910.001]
  • [Cites] Arthritis Rheum. 2003 Jan;48(1):231-9 [12528124.001]
  • [Cites] J Heart Lung Transplant. 2000 Oct;19(10):951-6 [11044689.001]
  • [Cites] Am Heart J. 2004 Oct;148(4):635-40 [15459594.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] J Intern Med. 2003 Jun;253(6):643-52 [12755960.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1093-103 [15014182.001]
  • [Cites] Transplantation. 1988 Oct;46(4):598-9 [3176159.001]
  • [Cites] Clin Nephrol. 1994 Jul;42(1):67-8 [7923972.001]
  • [Cites] N Engl J Med. 1989 Aug 3;321(5):287-92 [2664517.001]
  • [Cites] Arthritis Rheum. 2002 Aug;47(4):356-60 [12209479.001]
  • [Cites] J Rheumatol. 2004 Aug;31(8):1575-81 [15290738.001]
  • [Cites] Ann Intern Med. 1999 Nov 16;131(10):756-9 [10577299.001]
  • [Cites] J Rheumatol. 2005 May;32(5):773-7 [15868608.001]
  • [Cites] Eur J Drug Metab Pharmacokinet. 1989 Oct-Dec;14(4):317-22 [2633927.001]
  • [Cites] Am J Med. 1990 May;88(5):553 [2337116.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Dec;99(4):266-70 [9491303.001]
  • [Cites] Transplant Proc. 1995 Jun;27(3):2189-90 [7792928.001]
  • [Cites] Arch Intern Med. 1991 Apr;151(4):726-32 [2012455.001]
  • [Cites] J Rheumatol. 2002 Sep;29(9):1942-9 [12233890.001]
  • [Cites] Nephron. 1995;70(3):307-13 [7477618.001]
  • [Cites] J Clin Pharm Ther. 1999 Dec;24(6):397-408 [10651972.001]
  • [Cites] Nephron. 1996;74(2):318-23 [8893148.001]
  • [Cites] J Rheumatol. 1993 Apr;20(4):718-20 [8496871.001]
  • [Cites] J Rheumatol. 2001 Oct;28(10):2294-7 [11669172.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):177 [1967475.001]
  • [Cites] Muscle Nerve. 1999 Dec;22(12):1631-6 [10567074.001]
  • [Cites] J Hepatol. 1994 Mar;20(3):376-9 [8014449.001]
  • [Cites] Hepatology. 1992 May;15(5):899-903 [1568732.001]
  • [Cites] Arthritis Rheum. 1991 Dec;34(12 ):1489-94 [1747133.001]
  • [Cites] Arthritis Rheum. 2004 Mar;50(3):937-43 [15022337.001]
  • [Cites] J Clin Invest. 1984 Jun;73(6):1719-30 [6725556.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jun;16(6):1301 [11390746.001]
  • [Cites] Transplant Proc. 1995 Oct;27(5):2722-4 [7482890.001]
  • [Cites] Kidney Int. 2001 Jul;60(1):266-71 [11422760.001]
  • [Cites] Ann Rheum Dis. 1998 Sep;57(9):545-9 [9849314.001]
  • [Cites] J Clin Pharmacol. 1980 Oct;20(10):560-4 [7440763.001]
  • [Cites] Drugs. 2004;64(21):2399-416 [15481999.001]
  • [Cites] BioDrugs. 2001;15(4):261-78 [11437691.001]
  • [Cites] Am J Surg. 1988 Nov;156(5):397-400 [3056057.001]
  • [Cites] Heart. 2002 Mar;87(3):229-34 [11847159.001]
  • [Cites] JAMA. 1991 Dec 4;266(21):3004-7 [1820473.001]
  • [Cites] Arthritis Rheum. 2000 Aug;43(8):1891-6 [10943882.001]
  • [Cites] J Rheumatol. 2000 Sep;27(9):2232-6 [10990239.001]
  • [Cites] Clin Ther. 2004 Mar;26(3):399-406 [15110132.001]
  • [Cites] Transplantation. 1998 Jul 27;66(2):268-71 [9701277.001]
  • [Cites] Ann Rheum Dis. 1992 Nov;51(11):1267-8 [1466611.001]
  • [Cites] Transplant Proc. 1990 Feb;22(1):37-40 [1689893.001]
  • [Cites] Metabolism. 1988 Mar;37(3):217-20 [3278190.001]
  • [Cites] Transplantation. 1987 Feb;43(2):197-204 [3544376.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1277-81 [15094272.001]
  • [Cites] Semin Arthritis Rheum. 1981 May;10(4):231-54 [6787706.001]
  • [Cites] Am J Med. 2005 Aug;118(8):816-26 [16084170.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1329 [9010071.001]
  • [Cites] J Rheumatol. 1993 Dec;20(12):2171 [8014955.001]
  • [Cites] Clin Nephrol. 2001 Jan;55(1):39-44 [11200866.001]
  • [Cites] Arthritis Rheum. 1965 Jun;8:361-7 [14291431.001]
  • [Cites] J Heart Lung Transplant. 2004 May;23(5 Suppl):S187-93 [15093804.001]
  • [Cites] Arthritis Rheum. 2005 Jan;52(1):283-9 [15641075.001]
  • [Cites] Transplantation. 2001 Nov 27;72(10):1689-91 [11726834.001]
  • [Cites] J Rheumatol. 1999 Jan;26(1):136-40 [9918254.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):1704-5 [12962765.001]
  • [Cites] Ann Rheum Dis. 2001 Oct;60(10):984-6 [11589178.001]
  • [Cites] Muscle Nerve. 2003 Feb;27(2):142-56 [12548521.001]
  • [Cites] J Rheumatol. 1975 Dec;2(4):437-45 [1206675.001]
  • [Cites] Transplantation. 1994 Jul 27;58(2):245-7 [7726891.001]
  • [Cites] Arthritis Rheum. 1993 Sep;36(9):1274-85 [8216421.001]
  • [Cites] BMJ. 2002 Jun 22;324(7352):1488-92 [12077033.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):190-5 [2916461.001]
  • [Cites] Am Heart J. 2002 Oct;144(4):E6 [12360175.001]
  • [Cites] Kidney Int Suppl. 1998 Dec;68:S135-9 [9839298.001]
  • [Cites] Hypertension. 2003 Jun;41(6):1183-90 [12707287.001]
  • [Cites] Aust N Z J Med. 2000 Oct;30(5):567-72 [11108066.001]
  • [Cites] Clin Nephrol. 1990 Mar;33(3):154 [2323116.001]
  • [Cites] Hypertension. 1994 Sep;24(3):297-300 [8082935.001]
  • [Cites] Adv Exp Med Biol. 1974;41:581-96 [4832585.001]
  • [Cites] Nephrol Dial Transplant. 1987;2(5):380-1 [3122121.001]
  • [Cites] Arthritis Rheum. 2004 Feb;50(2):598-606 [14872504.001]
  • [Cites] Transplantation. 2000 Apr 15;69(7):1252-60 [10798738.001]
  • [Cites] Arthritis Rheum. 2002 Nov;46(11):3026-33 [12428246.001]
  • [Cites] Med J Aust. 2001 Aug 20;175(4):214-7 [11587283.001]
  • [Cites] Rev Rhum Engl Ed. 1995 Feb;62(2):86-90 [7600077.001]
  • [Cites] Arthritis Rheum. 2004 Jun 15;51(3):321-5 [15188314.001]
  • [Cites] Nephrol Dial Transplant. 2003 Oct;18(10):2147-53 [13679494.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Apr;18(2):111-24 [15121034.001]
  • [Cites] Nephrol Dial Transplant. 2001 Aug;16(8):1545-9 [11477152.001]
  • [Cites] J Rheumatol. 2001 Mar;28(3):577-80 [11296962.001]
  • [Cites] Ann Rheum Dis. 2000 Jul;59(7):539-43 [10873964.001]
  • [Cites] Transplant Proc. 1992 Oct;24(5):1773-4 [1412837.001]
  • [Cites] Hypertension. 1995 Jan;25(1):77-81 [7843758.001]
  • [Cites] Arthritis Rheum. 1991 Jul;34(7):894-903 [2059236.001]
  • [Cites] Am J Med. 1986 Sep;81(3):419-24 [3752142.001]
  • [Cites] Arch Phys Med Rehabil. 1990 May;71(6):426-7 [2334290.001]
  • [Cites] J Clin Epidemiol. 1997 Aug;50(8):953-9 [9291881.001]
  • [Cites] J Gastroenterol Hepatol. 2002 May;17(5):625-6 [12084041.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1813-6 [9369411.001]
  • [Cites] Arthritis Rheum. 1988 Jun;31(6):803-5 [2454635.001]
  • [Cites] Transplant Proc. 1999 Feb-Mar;31(1-2):1366-9 [10083606.001]
  • [Cites] Kidney Int Suppl. 2002 May;(80):78-84 [11982818.001]
  • [Cites] Transplantation. 1997 Oct 15;64(7):1087-8 [9381537.001]
  • [Cites] J Clin Rheumatol. 2004 Jun;10(3):105-9 [17043480.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):247-58 [14730623.001]
  • [Cites] Transplantation. 1999 Apr 15;67(7):1036-42 [10221490.001]
  • [Cites] J Rheumatol. 2002 Jul;29(7):1350-5 [12136887.001]
  • [Cites] Nephrol Dial Transplant. 1996 Jan;11(1):153-8 [8649625.001]
  • [Cites] Ann Surg. 1985 Feb;201(2):142-57 [3882063.001]
  • [Cites] Ann Pharmacother. 2001 Mar;35(3):365-8 [11261536.001]
  • [Cites] Am J Kidney Dis. 1994 Mar;23(3):347-51 [8128934.001]
  • [Cites] Semin Arthritis Rheum. 1998 Aug;28(1):48-59 [9726336.001]
  • [Cites] J Pharmacol Exp Ther. 1992 Apr;261(1):50-5 [1348538.001]
  • [Cites] Arch Intern Med. 2005 Apr 11;165(7):742-8 [15824292.001]
  • [Cites] Semin Arthritis Rheum. 1990 Jun;19(6):329-36 [2196674.001]
  • [Cites] Am J Med. 1992 Sep;93(3):354-5 [1482484.001]
  • [Cites] J Rheumatol. 2000 Jun;27(6):1501-5 [10852278.001]
  • [Cites] Liver. 1995 Feb;15(1):25-9 [7776854.001]
  • [Cites] Transplantation. 1990 Jun;49(6):1196-8 [2360262.001]
  • [Cites] Nephron. 1998 Dec;80(4):450-7 [9832645.001]
  • [Cites] J Rheumatol. 1993 Jan;20(1):111-3 [8441139.001]
  • [Cites] Am J Kidney Dis. 1987 Nov;10(5):369-72 [3314490.001]
  • [Cites] Nephrol Dial Transplant. 1999 Feb;14(2):384-8 [10069193.001]
  • [Cites] Nephrol Dial Transplant. 2000 May;15(5):644-9 [10809805.001]
  • [Cites] J Rheumatol. 1991 Feb;18(2):264-9 [2023222.001]
  • [Cites] Ann Rheum Dis. 1997 Jan;56(1):22-6 [9059136.001]
  • [Cites] J Rheumatol. 2000 Jun;27(6):1334-7 [10852250.001]
  • [Cites] Nephrol Dial Transplant. 1998 Dec;13(12):3245-7 [9870505.001]
  • [Cites] Transplantation. 2001 Nov 27;72(10):1703-5 [11726837.001]
  • [Cites] Proc Soc Exp Biol Med. 1995 Nov;210(2):93-101 [7568290.001]
  • [Cites] Ann Rheum Dis. 2003 Jun;62(6):572-5 [12759298.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Jan;268(1):388-95 [7905530.001]
  • [Cites] J Rheumatol. 1994 Apr;21(4):696-9 [8035395.001]
  • [Cites] Hypertension. 1993 Sep;22(3):339-47 [8349327.001]
  • [Cites] S Afr Med J. 1981 May 9;59(20):701-6 [7221794.001]
  • [Cites] Lancet. 1985 Jan 19;1(8421):128-30 [2857212.001]
  • [Cites] Clin Transplant. 1999 Oct;13(5):375-9 [10515217.001]
  • [Cites] Arthritis Rheum. 1973 Jul-Aug;16(4):431-45 [4147308.001]
  • [Cites] Arthritis Rheum. 1989 Nov;32(11):1443-52 [2554932.001]
  • [Cites] J Intern Med. 1990 Jul;228(1):69-71 [2384739.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1117-8 [15571212.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 5;206(1):15-21 [7529496.001]
  • [Cites] Drugs. 2003;63(1):33-45 [12487621.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2633-9 [15334478.001]
  • [Cites] Drugs. 1977 Nov;14(5):349-66 [338280.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5734-42 [15100320.001]
  • [Cites] J Rheumatol. 2001 Jul;28(7):1640-6 [11469473.001]
  • [Cites] N Engl J Med. 1987 Jun 18;316(25):1562-8 [3035372.001]
  • [Cites] Curr Opin Rheumatol. 2001 May;13(3):240-4 [11333356.001]
  • [Cites] Transplant Proc. 2000 Feb;32(1):199 [10701023.001]
  • [Cites] Rheumatology (Oxford). 2003 Feb;42(2):321-5 [12595630.001]
  • [Cites] Lancet. 1985 Feb 23;1(8426):453 [2857822.001]
  • [Cites] Transplant Proc. 2003 Aug;35(5):1909-10 [12962844.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Apr 15;200(1):142-8 [7513156.001]
  • [Cites] J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S7-11 [11347860.001]
  • [Cites] Arthritis Rheum. 1997 May;40(5):955-65 [9153559.001]
  • [Cites] Nephrol Dial Transplant. 2001 May;16(5):1034-7 [11328912.001]
  • [Cites] Kidney Int. 1985 Nov;28(5):767-74 [3910916.001]
  • [Cites] Am J Med. 1992 Feb;92(2):141-6 [1543197.001]
  • [Cites] Arch Intern Med. 2003 Mar 10;163(5):553-64 [12622602.001]
  • [Cites] Transplantation. 1996 Jun 15;61(11):1661-2 [8669118.001]
  • [Cites] Transplantation. 1991 Jul;52(1):64-7 [1858156.001]
  • [Cites] Transplant Proc. 1987 Feb;19(1 Pt 2):1829-30 [3079042.001]
  • [Cites] Nephrol Dial Transplant. 2000 Dec;15(12):1993-9 [11096145.001]
  • [Cites] Transplant Proc. 1998 Jun;30(4):1243-4 [9636505.001]
  • [Cites] Eur J Radiol. 2000 Dec;36(3):123-5 [11091009.001]
  • [Cites] Transplantation. 1997 May 15;63(9):1370-1 [9158039.001]
  • [Cites] Nephrol Dial Transplant. 2003 Mar;18(3):603-6 [12584286.001]
  • [Cites] Transplant Proc. 1992 Aug;24(4):1391-2 [1496597.001]
  • [Cites] Br J Rheumatol. 1984 Aug;23(3):203-9 [6743968.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):916-23 [15751090.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2765-75 [12384937.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(5):548-51 [8090336.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343 (21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Aust N Z J Med. 1987 Jun;17(3):301-4 [3314832.001]
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):267-72 [15647434.001]
  • [Cites] Arthritis Rheum. 1994 Nov;37(11):1709 [7980683.001]
  • [Cites] Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):397-414 [15107595.001]
  • [Cites] J Cell Biochem. 2003 Jul 1;89(4):791-9 [12858344.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):305-10 [9164871.001]
  • (PMID = 16392875.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Glucocorticoids; 0 / Gout Suppressants; 0 / Immunosuppressive Agents
  • [Number-of-references] 197
  •  go-up   go-down






Advertisement